Close Menu

Not This Time

The first human stem-cell based drug failed two late-stage clinical trials, reports the New York Times. The drug, Prochymal, from Osiris Therapeutics was made from mesenchymal stem cells from healthy young adults and was found to be no more effective than placebo in treating graft-versus-host disease. Prochymal did, however, appear to have an effect in a subset of patients. "Prochymal is having a clear effect in the liver, and that is the most underserved patient population," CEO C.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.